The Stock
Trading Information
Lipigon Pharmaceuticals AB is publicly traded on the Nasdaq First North Growth Market. The company has issued shares under a single class of stock, with the stock symbol LPGO and ISIN code SE0015382072.
Top Shareholders
Development of Share Capital
On the balance sheet date of June 30, 2023, the total number of shares amounted to 80,015,646 with a par value of approximately 0.11 SEK. The share capital amounted to 9,016,779 SEK. All shares have one voting right.
| Date | Transaction | Number of Common Shares | Increase in Share Capital | Invested Amount (SEK) |
|---|---|---|---|---|
| 2010-06-07 | Formation | 50 000 | 50 000 | 50 000 |
| 2016-02-04 | Share Issuance | 3 000 | 53 000 | 3 000 |
| 2016-05-12 | Share Issuance | 5 301 | 58 301 | 503 505 |
| 2016-09-06 | Share Issuance | 5 301 | 63 602 | 503 595 |
| 2016-12-19 | Share Issuance | 10 600 | 74 202 | 500 320 |
| 2017-02-01 | Share Issuance | 13 144 | 87 346 | 3 100 012 |
| 2018-01-19 | Share Issuance | 9 000 | 96 346 | 1 800 000 |
| 2018-06-18 | Share Issuance | 8 875 | 105 221 | 1 775 000 |
| 2019-05-08 | Share Issuance | 28 059 | 133 280 | 7 996 815 |
| 2020-07-07 | Share Issuance | 88 572 | 221 852 | 16 651 536 |
| 2020-08-28 | Split 1:20 | 4 215 188 | 221 852 | - |
| 2020-08-28 | Fund Issuance | - | 500 000 | - |
| 2020-12-02 | Share Issuance | 295 858 | 33 339 | 3 000 000 |
| 2021-02-23 | Share Issuance | 5 000 000 | 563 439 | 55 991 872 |
| 2022-06-21 | Share Issuance | 10 511 526 | 1 184 519 | 22 599 781 |
| 2023-04-19 | Share Issuance | 58 686 425 | 6 613 237 | 28 810 658 |
| 2023-05-04 | Share Issuance | 1 084 797 | 122 243 | 532 554 |
| 2023-12-20 | Share Issuance | 46 406 635 | 11 842 694 | 13 921 991 |
| Total | 126 422 281 | 20 859 472 | 143 818 649 |
Subscription Warrant Program
Below is a summary of the company's warrant program as of June 30, 2023. If all warrants are fully exercised, the dilution of current shareholders would be 106%.
| Program | Holders | Number of Warrants | Exercise Price | Value per Allocated Warrant | Volatility, % | Risk-free Interest Rate, % | Subscription Right per Option | Subscription (year) |
|---|---|---|---|---|---|---|---|---|
| Warrants 2021/2024:1 | Employees | 365 700 | 26,3(l) | 0,53 | 43,5 | -0,32 | 1,06(l) | 2024 |
| Warrants 2021/2024:2 | Board of Directors | 220 800 | 26,3(l) | 0,53 | 43,5 | -0,32 | 1,06(l) | 2024 |
| TO3, Share Issue 2024 | Other Shareholders | 25 616 238 | (ll) | - | - | - | 1 | 2024 |
| Warrants 2023/2027 | Employees | 7 380 000 | (lll) | Not decided | Not decided | Not decided | 1 | 2027 |
| Total | 84 815 214 | - | - | - | - | - | - |
(I) Adjusted after completed new issuance in accordance with the warrant terms.
(II) 70 percent of the volume-weighted average price of the Company's stock over a 10-day trading period starting from the day after the Company has informed through a press release about the last patient visit in the Phase II study for the Company's drug candidate, Lipisense, or in the absence of such announcement, during the period from May 6, 2024, to May 20, 2024, but not less than the stock's nominal value and no more than 0.8 kronor.
(III) 200 percent of the volume-weighted average price according to Nasdaq First North Growth Markets' official price list for the stock over the ten trading days immediately preceding the offer of the subscription warrant, but not less than the stock's nominal value.
Information about Nasdaq First North Growth Market
Nasdaq First North Growth Market is a registered SME marketplace for growth companies, following the Directive on Markets in Financial Instruments (EU 2014/65) implemented in the national legislation of Denmark, Finland, and Sweden. The marketplace is part of the Nasdaq Group. Issuers on Nasdaq First North Growth Market are not subject to the regulations that apply to issuers whose shares are listed on a regulated market, as defined in EU legislation (and implemented in national legislation). Instead, they are subject to less extensive rules and regulations tailored to smaller growth companies. The risk of investing in an issuer on Nasdaq First North Growth Market may, therefore, be higher than investing in an issuer listed on a regulated market. All issuers with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors compliance with the rules. Nasdaq approves issuers' applications for admission to trading.